Bottom line
In lab studies and in mice with colitis (inflammation of the large bowel), KPV showed signs of calming inflammation. The FDA found no studies of KPV in people. It also found no data from people given KPV in any way. It is unknown whether KPV helps or harms people. The lab and animal studies cannot predict the answer.38
- Evidence in people
- No useful studies of KPV given to people were found
- Approval status
- KPV is not approved by the FDA. The FDA reviewed two forms, KPV free base and KPV acetate. Neither one is an ingredient in an FDA-approved drug. In July 2026, FDA staff concluded that the available information weighed against putting either form on the 503A Bulks List (the FDA's list of ingredients pharmacies may use to make custom medicines).312
- Biggest unknown
- There is no useful data on KPV given to people. So in people, it is unknown how much of it gets into the body. It is also unknown how the body absorbs, spreads and clears it. Its effects on health and its side effects are unknown. So are its interactions with other medicines, its longer-term risks, and whether the body's immune system reacts against it.36
Where research exists
Filled markers show which stages of research this guide covers. They don't rate how well KPV works, how safe it is, or how good the studies are.
- Health results in peopleNo useful evidence found
- Blood tests and body measurements in peopleNo useful evidence found
- Animal studiesCovered in this guide
- Lab studies in cellsCovered in this guide
- Untested idea or marketing claimCovered in this guide
What KPV is
KPV is a tripeptide. That means it is a chain of three amino acids, the building blocks of proteins. Its three amino acids are lysine, proline, and valine. It has been described as a piece linked to the biology of a hormone called alpha-melanocyte-stimulating hormone.38
KPV is a common name. It has no established United States Adopted Name (an official U.S. name for a drug ingredient). The FDA reported several salts and derivatives (related chemical versions) sold under that name. So a label or paper may not make clear which substance it describes.3
KPV free base and KPV acetate are different active drug ingredients. Their chemical structures differ. Their physical properties may differ too. So may their safety, how well they work, and how the body absorbs, spreads and clears them. That means one cannot automatically stand in for the other.32
Compounding means a pharmacy making a custom medicine. In its compounding review, the FDA judged both forms poorly characterized. That means not enough was known about exactly what they are. Naming was inconsistent. There was too little information specific to each form on its identity, purity, and impurities. The same was true for aggregation (peptide molecules clumping together), controls against germs, and how the proposed products would perform.3
Why people are interested in KPV
Lab experiments suggest KPV may affect the chemical signals involved in inflammation. The most-cited gut research looked at how PepT1, a protein that carries small peptides into cells, takes in KPV. It also looked at markers of inflammation further down that chain. All of this was in lab experiments.8
The FDA found KPV being promoted for conditions involving inflammation, wound healing, skin health, nerve damage, and stroke. These uses go well beyond what the evidence has shown.3
“Anti-inflammatory” can describe several things. It can describe a chemical change in a lab dish, or a tissue marker in a mouse. It can also describe a symptom in a person, or a change in disease large enough to matter to patients. These are four separate claims, and each needs its own evidence.83
Studies in people
The FDA found no studies in people of KPV free base or KPV acetate. It found no data from people given either form in any way. It also found no case reports (reports on single patients). It found no human studies of how the body absorbs, spreads and clears KPV. It found none on what KPV does in the body either.3
KPV was nominated for wound healing and for conditions involving inflammation. (A nomination asks the FDA to consider an ingredient for a compounding list.) Whoever nominated KPV gave no evidence from studies in people for these uses. The FDA found no information on people using it either. So the available record gives no way to judge whether KPV works.3
Some experiments used human intestinal cell lines, which are human gut cells grown in a lab. These are lab studies. The cells came from people, but no patient received KPV. No symptom, body function, healing, hospital stay, or disease outcome was measured.8
With no studies of KPV given to people, its benefits and risks in people are unknown. Saying “no side effects found” would mislead. The reason is that KPV use in people has not been studied well enough.3
Laboratory and animal studies
A 2008 study reported that human gut cells grown in a lab took up KPV through the PepT1 transporter. It also reported changes in inflammation signals in these experiments. Under the study's conditions, this supports an idea about how KPV might work. Whether it works as a treatment for patients is a separate question.8
The same paper reported changes in weight loss, enzyme activity in tissue, and markers of inflammation in mice with colitis. Mouse models like these help test ideas about biology. But they miss much of the complexity of inflammatory bowel disease (long-term inflammation of the gut) in people. They also miss much of how it is treated and the outcomes that matter to patients.8
The FDA noted that some of the lab work cited used tissue models or skin from dead bodies. The nomination, however, proposed topical products (products put on the skin). Lab tests of how KPV passes into skin or acts on cells leave open whether a finished skin product heals a human wound. They also leave open whether it safely treats a skin disease.3
Moving KPV toward becoming a treatment would take several things. It would need a clearly identified substance and product form. It would need data on how much reaches the body. It would need studies that test different doses and check for harmful effects. And it would need controlled studies in people that measure outcomes for each specific disease. Controlled studies compare people who get a treatment with people who don't. Studies of how KPV acts cannot stand in for any of these steps.37
Safety
The FDA found no studies in people and no data from people given KPV. So it could not describe KPV's side effects: how often they happen, how serious they are, or when they appear. It also could not say whether they go away, or what makes someone more likely to get them. Having no safety-monitoring data gives no reassurance about safety.3
Clumping of peptide molecules can change how much of a drug the body can use, and how the drug acts. It can also make the body's immune system more likely to react against the drug. The FDA found no human data on clumping or immune reactions for KPV-related substances. So it found too little information to conclude that those risks are absent.36
Making peptides in a lab can leave unwanted material behind. This can include shortened peptide chains, related peptides, leftover chemicals and solvents from the process, and clumps. A single headline purity figure may miss some impurities that matter, or leave them unchecked.36
Safety also depends on the finished product and how it is taken. A cream, a nasal product, a product taken by mouth, and an injection each raise their own questions. These cover the product's makeup, how free it is of germs, how much reaches the body, and how it is given. That holds even when all are sold under the same three-letter name.37
The 2026 FDA compounding review
The original KPV nomination was withdrawn. The FDA still chose to review KPV free base and KPV acetate on its own. One reason was that the nomination was unclear about which substance it meant. Another was that the FDA found significant safety concerns.3
The July 2026 review looked at whether KPV might be placed on the 503A Bulks List. It covered the nominated uses in wound healing and conditions involving inflammation. No application for approval to sell a drug was under review.32
FDA staff concluded that several factors weighed against adding either form of KPV to the 503A Bulks List. Both forms were poorly characterized. Their past use in compounding was unknown. And there was no information from people on how well they work or how safe they are.3
The advisory committee in this review is the Pharmacy Compounding Advisory Committee (a panel that advises the FDA on compounding). Its recommendations are nonbinding, meaning the FDA does not have to follow them. The committee's meeting approved nothing. A recommendation against putting KPV on the list also stops short of banning KPV in every research or legal setting.51
KPV is listed on a current FDA page about compounding ingredients that may pose safety risks. The page points out the missing information on people given KPV. It also flags possible concerns about immune reactions and impurities. The page is a risk assessment by a regulator, with a narrow focus. It covers far less than a complete account of KPV's safety in patients would.4
Questions to ask
Where does a claim come from? It might come from results in people, data from people given KPV, a mouse study, human gut cells grown in a lab, or marketing. Is that source named every time the claim is repeated?38
Is the material KPV free base, KPV acetate, or another related form? Beyond the common name on the label, what testing of that exact substance confirms what it is and how pure it is?3
Are the gaps in what is known stated plainly? These include how KPV acts in people, its effects on health, its side effects, its interactions with other medicines, and immune risk. What evidence would help fill those gaps?37
How the compounding review works
The July 2026 meeting dealt with a compounding process set by law. This process is separate from FDA drug approval. It has four steps.
- A substance is nominated
A nomination asks the FDA to consider whether a bulk drug substance (an active ingredient in raw form) may qualify for a compounding list set by law. Drug approval needs a separate application. - FDA staff assess the record
The FDA looks at what is known about exactly what the substance is. It also looks at past use, how well it works, and how safe it is, in light of the nomination. It prepares a public briefing memo as well. - The advisory committee gives nonbinding advice
The Pharmacy Compounding Advisory Committee discusses the questions and advises the FDA. Its recommendation is advice only. It approves nothing. - FDA considers final agency action
The FDA weighs the committee's input and completes its reviews. Only after that would it take any final agency action (an official FDA decision). A meeting or a staff position on its own never counts as that final step.
A staff memo is the staff's assessment, and an advisory committee recommendation is advice. Neither is an FDA decision.
References
- 1July 23–24, 2026 Meeting of the Pharmacy Compounding Advisory CommitteeU.S. Food and Drug Administration · 2026-07-23 · FDA document
The meeting record lists the substances proposed for the list and the uses discussed. The committee's votes are advice only. They are not an FDA approval or a final FDA decision.
- 22026 PCAC Voting QuestionsU.S. Food and Drug Administration · 2026-07-23 · FDA document
The questions ask whether the free-base and acetate forms should be placed on the 503A bulks list. Drug approval was outside their scope.
- 3KPV Free Base and Acetate Salt: Pharmacy Compounding Advisory Committee Briefing DocumentU.S. Food and Drug Administration · 2026-07-23 · FDA document
The FDA found no studies of KPV in people and no data from people given it in any way. The memo is the FDA staff's review, written for the compounding review.
- 4Certain Bulk Drug Substances for Use in Compounding that May Present Significant Safety RisksU.S. Food and Drug Administration · 2026-07-23 · FDA document
FDA's current compounding-risk summary includes BPC-157, KPV, MOTS-c, and the thymosin beta-4 fragment known as TB-500. The listing flags risks and stops well short of a complete safety profile.
- 5Advisory Committees: Critical to the FDA's Product Review ProcessU.S. Food and Drug Administration · 2018-01-04 · FDA document
The FDA explains that the committee only gives advice, which the FDA does not have to follow, and that the FDA makes the final decision.
- 6Immunogenicity Risk of Peptide Drug Products: Scientific and Regulatory ConsiderationsU.S. Food and Drug Administration · 2024-09-11 · FDA document
How a peptide is made up and given, clumping, and impurities can all change the risk of immune reactions. This is a general rule. Each product still has to be tested on its own.
- 7Clinical Pharmacology Considerations for Peptide Drug ProductsU.S. Food and Drug Administration · 2023-12-01 · FDA document
This is draft advice from the FDA, which drug makers do not have to follow, on developing peptide drugs. It lists questions each product must answer: how the body absorbs and clears it, use in people with liver or kidney problems, drug interactions, effects on heart rhythm, and immune reactions.
- 8PepT1-Mediated Tripeptide KPV Uptake Reduces Intestinal InflammationGastroenterology (PubMed record) · 2008-01-01 · Animal or lab study
This study used human cell lines and mouse colitis models. No patients received KPV, and no clinical outcomes were tested.